35. 天疱瘡 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 99 / 薬物数 : 124 - (DrugBank : 36) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 169
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
ALXN1830
Alexion Pharmaceuticals
2017 Phase 1/Phase 2 NCT03075904 United States;
ARGX-113
ARGEN-X BVBA
2018 Phase 2 EUCTR2017-002333-40-IT Germany;Hungary;Israel;Italy;Romania;Ukraine;
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx
2017 Phase 2 NCT03334058 Germany;Hungary;Israel;Italy;Ukraine;
argenx BV
2021 Phase 3 EUCTR2020-002917-16-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002917-16-HU Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002917-16-GR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002917-16-BG Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx BVBA
2018 Phase 2 EUCTR2017-002333-40-DE Germany;Hungary;Israel;Italy;Romania;Ukraine;
2017 Phase 2 EUCTR2017-002333-40-HU Germany;Hungary;Israel;Italy;Romania;Ukraine;
Acetaminophen/paracetamol
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States;
Ad26.COV2.S
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
Antihistamine (cetirizine or equivalent)
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States;
Azathioprine
Dermatological Department, West China hospital, Sichuan University
2016 Phase 1 study ChiCTR-OIC-17011759 China;
Tehran University of Medical Sciences
2008 Phase 2 NCT00626678 Iran, Islamic Republic of;
BNT162b2
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
CELLCEPT®
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
Carboxymethylcellulose with ionic silver (Aquacel Ag)
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico;
CellCept 500 mg comprimidos recubiertos
Aspreva pharmaceuticals Corporation
2006 - EUCTR2004-000526-75-ES Spain;
CellCept®500 mg comprimidos
Aspreva pharmaceuticals Corporation
2006 - EUCTR2004-000526-75-ES Spain;
Cellcept® in autoimmune bullous dermatoses
University Hospital, Limoges
2016 Phase 3 NCT02993133 France;
Cellulose acetate with petrolatum
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico;
Cohort 1: 1.0 x 10^8 PolyTregs
National Institute of Allergy and Infectious Diseases (NIAID)
2017 Phase 1 NCT03239470 United States;
Cohort 2: 2.5x10^8 PolyTregs
National Institute of Allergy and Infectious Diseases (NIAID)
2017 Phase 1 NCT03239470 United States;
Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
University of Luebeck
2008 Phase 2 NCT00656656 Germany;
Corticosteroids'therapy
University Hospital, Rouen
2019 Phase 3 NCT03790293 -
Cotton gauze with petrolatum
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico;
Cyclophosphamide
Johns Hopkins University
1999 Phase 2 NCT00010413 United States;
New York University School of Medicine
2007 Phase 2 NCT00483119 United States;
DSG3-CAART
Cabaletta Bio
2020 Phase 1 NCT04422912 United States;
Dapsone
Jacobus Pharmaceutical
1996 Phase 2 NCT00429533 United States;
Dermoval
University Hospital, Rouen
2001 - NCT00213421 France;
Dexamethasone (50mg 1dd6, 3 consecutive days/month)
University Medical Centre Groningen
2001 Phase 2/Phase 3 NCT00127764 Netherlands;
Dexamethasone 0.5mg/5ml solution in Mucolox™
University of California, San Francisco
2020 Phase 2 NCT04540133 United States;
Efgartigimod
ARGEN-X BVBA
2018 Phase 2 EUCTR2017-002333-40-IT Germany;Hungary;Israel;Italy;Romania;Ukraine;
argenx BVBA
2018 Phase 2 EUCTR2017-002333-40-DE Germany;Hungary;Israel;Italy;Romania;Ukraine;
2017 Phase 2 EUCTR2017-002333-40-HU Germany;Hungary;Israel;Italy;Romania;Ukraine;
Efgartigimod PH20 SC
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx
2021 Phase 3 NCT04598477 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 NCT04598451 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx BV
2021 Phase 3 EUCTR2020-002917-16-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002917-16-DE Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002915-23-DE Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002917-16-HU Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002917-16-GR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002917-16-BG Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-HU Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-GR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-BG Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
Enbrel (Etanercept)
Massachusetts General Hospital
2004 Phase 2 NCT00135720 United States;
Filgrastim
Johns Hopkins University
1999 Phase 2 NCT00010413 United States;
GSK1841157
Glaxo Group Ltd
2015 Phase 3 EUCTR2013-001370-20-PL Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States;
2015 - EUCTR2013-001370-20-FR Australia;China;Croatia;France;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States;
2014 Phase 3 EUCTR2013-001370-20-IT Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States;
2014 Phase 3 EUCTR2013-001370-20-GR Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States;
Novartis Pharma AG
2014 Phase 3 EUCTR2013-001370-20-HR Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States;
General Corticotherapy
University Hospital, Rouen
2009 Phase 3 NCT00784589 France;
Gold
Peking University School and Hospital of Stomatology
2018 Phase 0 ChiCTR2100042023 China;
Peking University stomatological hospital
2018 Phase 0 ChiCTR2100042024 China;
Hematopoietic stem cell transplantation
Richard Burt, MD
2002 Phase 1 NCT00278642 United States;
INCB050465 HYDROCHLORIDE
INCYTE CORPORATION
2019 Phase 2 EUCTR2018-002146-37-IT Canada;France;Italy;
Incyte Corporation
2019 Phase 2 EUCTR2018-002146-37-FR Canada;France;Italy;
IS (B cell depletion therapy)
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
IS (MMF or MPA)
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
IS (MTX)
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
IVIg
The University of Hong Kong
2020 Phase 2 NCT04400994 Hong Kong;
Ianalumab
Novartis Pharma Services AG
2013 Phase 2 EUCTR2013-001217-33-AT Austria;Bulgaria;Taiwan;United States;
Imatinib
Kabashima Kenji
2018 Phase 0 JPRN-jRCTs051180069 Japan;
Infliximab
National Institute of Allergy and Infectious Diseases (NIAID)
2006 Phase 2 NCT00283712 United States;
Intratect
Ruprecht-Karls-University Heidelberg
2013 Phase 2 EUCTR2013-000211-24-DE Germany;
Intravenous immunoglobulin
New York University School of Medicine
2007 Phase 2 NCT00483119 United States;
KC706
Kemia, Inc
2007 Phase 2 NCT00606749 United States;
MABTHERA®
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
MTX
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003540 China;
2011 - ChiCTR-TRC-12003539 China;
Mabthéra
CHU-Hôpitaux de Rouen
2009 - EUCTR2008-005266-31-FR France;
Mathéra
CHU-Hôpitaux de Rouen
2009 - EUCTR2008-005266-31-FR France;
Methotrexate
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003539 China;
Methylprednisolone
West China Hospital, Sichuna University
2019 - ChiCTR1800020382 China;
Micofenolato mofetilo
Aspreva pharmaceuticals Corporation
2006 - EUCTR2004-000526-75-ES Spain;
Moderna mRNA-1273
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
Mycophenolate Mofetil (MMF) 3 g/Day
Hoffmann-La Roche
2004 Phase 3 NCT00683930 Canada;Germany;India;Israel;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Mycophenolate Mofetil 2 g/Day
Hoffmann-La Roche
2004 Phase 3 NCT00683930 Canada;Germany;India;Israel;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Mycophenolate mofetil
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
Nanocrystalline silver (Acticoat)
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico;
ONO-4059
ONO PHARMACEUTICAL CO.,LTD.
2019 Phase 2 JPRN-JapicCTI-184231 Japan;
Ofatumumab
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States;
Novartis Pharmaceuticals
2013 Phase 3 NCT01920477 Australia;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United States;
PI-0824
Peptimmune
2003 Phase 1 NCT00063752 United States;
PRN1008
Principia Biopharma
2019 Phase 3 EUCTR2018-002261-19-GR Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002261-19-FR Australia;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002261-19-ES Australia;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
Principia Biopharma Inc.
2019 Phase 3 EUCTR2018-002261-19-IT Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
2016 Phase 2 NCT02704429 Australia;Croatia;France;Greece;Israel;
PRN1008 (Rilzabrutinib)
Principia Biopharma
2019 Phase 3 EUCTR2018-002261-19-HR Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002261-19-GB Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
2018 Phase 3 EUCTR2018-002261-19-BG Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
Principia Biopharma , Inc.
2019 Phase 3 EUCTR2018-002261-19-DE Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
PRN1008 Freebase
Principia Biopharma Australia Pty Ltd
2016 Phase 2 EUCTR2015-003564-37-HR Australia;Croatia;France;Greece;Israel;
2016 Phase 2 EUCTR2015-003564-37-GR Australia;Croatia;France;Greece;Israel;
Parsaclisib
Incyte Corporation
2019 Phase 2 NCT03780166 -
Prednison 10 mg GALEN
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Prednison 5 mg GALEN
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Prednison 50 mg GALEN
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Prednison20 mg GALEN
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Prednisone
CHU-Hôpitaux de Rouen
2009 - EUCTR2008-005266-31-FR France;
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003540 China;
2011 - ChiCTR-TRC-12003539 China;
Tehran University of Medical Sciences
2008 Phase 2 NCT00626678 Iran, Islamic Republic of;
West China Hospital, Sichuna University
2019 - ChiCTR1800020382 China;
argenx
2021 Phase 3 NCT04598477 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 NCT04598451 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
Prednisone/Prednisolone
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States;
RO0452294/V02
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
RO1061443/F02
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
Recombinant human interleukin-2 (rhIL-2)
Second Xiangya Hospital of Central South University
2020 Phase 2 NCT04023149 China;
Rilzabrutinib Oral Tablet
Principia Biopharma, a Sanofi Company
2019 Phase 3 NCT03762265 Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Rituximab
Department of Dermatology,Keio University School of Medicine
2016 Phase 2 JPRN-UMIN000024265 Japan;
2014 Phase 1,2 JPRN-UMIN000015451 Japan;
Funakoshi Takeru
2017 - JPRN-jRCTs031180405 Japan;
Hoffmann-La Roche
2015 Phase 3 NCT02383589 Argentina;Australia;Brazil;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
ISTITUTO DERMOPATICO IMMACOLATA
2007 - EUCTR2007-005711-26-IT Italy;
Kanaoka Miwa
2014 - JPRN-jRCTs031180220 Japan;
Keio University, School of Medicine
2017 - JPRN-UMIN000026004 Japan;
Rabin Medical Center
2010 - NCT01338103 Israel;
Research group of rare intractable dermatologial disorder
2010 Phase 2 JPRN-UMIN000004428 Japan;
The University of Hong Kong
2020 Phase 2 NCT04400994 Hong Kong;
University Hospital, Rouen
2019 Phase 3 NCT03790293 -
2011 Phase 3 NCT01299857 France;
2009 Phase 3 NCT00784589 France;
West China Hospital, Sichuna University
2019 - ChiCTR1800020382 China;
Rituximab (MABTHERA® or RITUXAN®).
University Hospital, Toulouse
2009 - NCT00960713 France;
Rituximab and Cyclophosphamide IV
Uprety Shraddha
2013 Phase 3 NCT01974518 India;
Sirolimus (formerly known as Rapamycin)
University of California, Irvine
2011 Early Phase 1 NCT01313923 United States;
TPM203
Topas Therapeutics GmbH
2019 Phase 1 EUCTR2019-001727-12-DE Germany;Israel;Italy;United Kingdom;
Tirabrutinib
ONO PHARMACEUTICAL CO.,LTD.
2019 Phase 2 JPRN-JapicCTI-184231 Japan;
Triamcinolone Acetonide
Cairo University
2016 Phase 3 NCT02828163 Egypt;
VAY736
Novartis Pharma Services AG
2013 Phase 2 EUCTR2013-001217-33-AT Austria;Bulgaria;Taiwan;United States;
Novartis Pharmaceuticals
2013 Phase 2 NCT01930175 Austria;Bulgaria;Germany;Israel;Italy;Taiwan;United Kingdom;United States;
WATER FOR INJECTION
Ruprecht-Karls-University Heidelberg
2013 Phase 2 EUCTR2013-000211-24-DE Germany;
Alexion Pharmaceuticals
2017 Phase 1/Phase 2 NCT03075904 United States;
ARGX-113
ARGEN-X BVBA
2018 Phase 2 EUCTR2017-002333-40-IT Germany;Hungary;Israel;Italy;Romania;Ukraine;
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx
2017 Phase 2 NCT03334058 Germany;Hungary;Israel;Italy;Ukraine;
argenx BV
2021 Phase 3 EUCTR2020-002917-16-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002917-16-HU Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002917-16-GR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002917-16-BG Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx BVBA
2018 Phase 2 EUCTR2017-002333-40-DE Germany;Hungary;Israel;Italy;Romania;Ukraine;
2017 Phase 2 EUCTR2017-002333-40-HU Germany;Hungary;Israel;Italy;Romania;Ukraine;
Acetaminophen/paracetamol
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States;
Ad26.COV2.S
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
Antihistamine (cetirizine or equivalent)
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States;
Azathioprine
Dermatological Department, West China hospital, Sichuan University
2016 Phase 1 study ChiCTR-OIC-17011759 China;
Tehran University of Medical Sciences
2008 Phase 2 NCT00626678 Iran, Islamic Republic of;
BNT162b2
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
CELLCEPT®
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
Carboxymethylcellulose with ionic silver (Aquacel Ag)
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico;
CellCept 500 mg comprimidos recubiertos
Aspreva pharmaceuticals Corporation
2006 - EUCTR2004-000526-75-ES Spain;
CellCept®500 mg comprimidos
Aspreva pharmaceuticals Corporation
2006 - EUCTR2004-000526-75-ES Spain;
Cellcept® in autoimmune bullous dermatoses
University Hospital, Limoges
2016 Phase 3 NCT02993133 France;
Cellulose acetate with petrolatum
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico;
Cohort 1: 1.0 x 10^8 PolyTregs
National Institute of Allergy and Infectious Diseases (NIAID)
2017 Phase 1 NCT03239470 United States;
Cohort 2: 2.5x10^8 PolyTregs
National Institute of Allergy and Infectious Diseases (NIAID)
2017 Phase 1 NCT03239470 United States;
Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
University of Luebeck
2008 Phase 2 NCT00656656 Germany;
Corticosteroids'therapy
University Hospital, Rouen
2019 Phase 3 NCT03790293 -
Cotton gauze with petrolatum
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico;
Cyclophosphamide
Johns Hopkins University
1999 Phase 2 NCT00010413 United States;
New York University School of Medicine
2007 Phase 2 NCT00483119 United States;
DSG3-CAART
Cabaletta Bio
2020 Phase 1 NCT04422912 United States;
Dapsone
Jacobus Pharmaceutical
1996 Phase 2 NCT00429533 United States;
Dermoval
University Hospital, Rouen
2001 - NCT00213421 France;
Dexamethasone (50mg 1dd6, 3 consecutive days/month)
University Medical Centre Groningen
2001 Phase 2/Phase 3 NCT00127764 Netherlands;
Dexamethasone 0.5mg/5ml solution in Mucolox™
University of California, San Francisco
2020 Phase 2 NCT04540133 United States;
Efgartigimod
ARGEN-X BVBA
2018 Phase 2 EUCTR2017-002333-40-IT Germany;Hungary;Israel;Italy;Romania;Ukraine;
argenx BVBA
2018 Phase 2 EUCTR2017-002333-40-DE Germany;Hungary;Israel;Italy;Romania;Ukraine;
2017 Phase 2 EUCTR2017-002333-40-HU Germany;Hungary;Israel;Italy;Romania;Ukraine;
Efgartigimod PH20 SC
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx
2021 Phase 3 NCT04598477 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 NCT04598451 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx BV
2021 Phase 3 EUCTR2020-002917-16-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002917-16-DE Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002915-23-DE Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002917-16-HU Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002917-16-GR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002917-16-BG Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-HU Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-GR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-FR Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-BG Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
Enbrel (Etanercept)
Massachusetts General Hospital
2004 Phase 2 NCT00135720 United States;
Filgrastim
Johns Hopkins University
1999 Phase 2 NCT00010413 United States;
GSK1841157
Glaxo Group Ltd
2015 Phase 3 EUCTR2013-001370-20-PL Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States;
2015 - EUCTR2013-001370-20-FR Australia;China;Croatia;France;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States;
2014 Phase 3 EUCTR2013-001370-20-IT Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States;
2014 Phase 3 EUCTR2013-001370-20-GR Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States;
Novartis Pharma AG
2014 Phase 3 EUCTR2013-001370-20-HR Australia;China;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Ukraine;United States;
General Corticotherapy
University Hospital, Rouen
2009 Phase 3 NCT00784589 France;
Gold
Peking University School and Hospital of Stomatology
2018 Phase 0 ChiCTR2100042023 China;
Peking University stomatological hospital
2018 Phase 0 ChiCTR2100042024 China;
Hematopoietic stem cell transplantation
Richard Burt, MD
2002 Phase 1 NCT00278642 United States;
INCB050465 HYDROCHLORIDE
INCYTE CORPORATION
2019 Phase 2 EUCTR2018-002146-37-IT Canada;France;Italy;
Incyte Corporation
2019 Phase 2 EUCTR2018-002146-37-FR Canada;France;Italy;
IS (B cell depletion therapy)
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
IS (MMF or MPA)
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
IS (MTX)
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
IVIg
The University of Hong Kong
2020 Phase 2 NCT04400994 Hong Kong;
Ianalumab
Novartis Pharma Services AG
2013 Phase 2 EUCTR2013-001217-33-AT Austria;Bulgaria;Taiwan;United States;
Imatinib
Kabashima Kenji
2018 Phase 0 JPRN-jRCTs051180069 Japan;
Infliximab
National Institute of Allergy and Infectious Diseases (NIAID)
2006 Phase 2 NCT00283712 United States;
Intratect
Ruprecht-Karls-University Heidelberg
2013 Phase 2 EUCTR2013-000211-24-DE Germany;
Intravenous immunoglobulin
New York University School of Medicine
2007 Phase 2 NCT00483119 United States;
KC706
Kemia, Inc
2007 Phase 2 NCT00606749 United States;
MABTHERA®
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
MTX
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003540 China;
2011 - ChiCTR-TRC-12003539 China;
Mabthéra
CHU-Hôpitaux de Rouen
2009 - EUCTR2008-005266-31-FR France;
Mathéra
CHU-Hôpitaux de Rouen
2009 - EUCTR2008-005266-31-FR France;
Methotrexate
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003539 China;
Methylprednisolone
West China Hospital, Sichuna University
2019 - ChiCTR1800020382 China;
Micofenolato mofetilo
Aspreva pharmaceuticals Corporation
2006 - EUCTR2004-000526-75-ES Spain;
Moderna mRNA-1273
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
Mycophenolate Mofetil (MMF) 3 g/Day
Hoffmann-La Roche
2004 Phase 3 NCT00683930 Canada;Germany;India;Israel;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Mycophenolate Mofetil 2 g/Day
Hoffmann-La Roche
2004 Phase 3 NCT00683930 Canada;Germany;India;Israel;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Mycophenolate mofetil
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
Nanocrystalline silver (Acticoat)
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015 - NCT02365675 Mexico;
ONO-4059
ONO PHARMACEUTICAL CO.,LTD.
2019 Phase 2 JPRN-JapicCTI-184231 Japan;
Ofatumumab
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States;
Novartis Pharmaceuticals
2013 Phase 3 NCT01920477 Australia;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United States;
PI-0824
Peptimmune
2003 Phase 1 NCT00063752 United States;
PRN1008
Principia Biopharma
2019 Phase 3 EUCTR2018-002261-19-GR Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002261-19-FR Australia;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002261-19-ES Australia;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
Principia Biopharma Inc.
2019 Phase 3 EUCTR2018-002261-19-IT Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
2016 Phase 2 NCT02704429 Australia;Croatia;France;Greece;Israel;
PRN1008 (Rilzabrutinib)
Principia Biopharma
2019 Phase 3 EUCTR2018-002261-19-HR Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002261-19-GB Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
2018 Phase 3 EUCTR2018-002261-19-BG Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
Principia Biopharma , Inc.
2019 Phase 3 EUCTR2018-002261-19-DE Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
PRN1008 Freebase
Principia Biopharma Australia Pty Ltd
2016 Phase 2 EUCTR2015-003564-37-HR Australia;Croatia;France;Greece;Israel;
2016 Phase 2 EUCTR2015-003564-37-GR Australia;Croatia;France;Greece;Israel;
Parsaclisib
Incyte Corporation
2019 Phase 2 NCT03780166 -
Prednison 10 mg GALEN
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Prednison 5 mg GALEN
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Prednison 50 mg GALEN
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Prednison20 mg GALEN
ARGENX BV
2020 Phase 3 EUCTR2020-002917-16-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002915-23-IT Australia;Bulgaria;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Prednisone
CHU-Hôpitaux de Rouen
2009 - EUCTR2008-005266-31-FR France;
Institute of dermatology, Chinese Academyof Medical Sciences
2011 - ChiCTR-TRC-12003540 China;
2011 - ChiCTR-TRC-12003539 China;
Tehran University of Medical Sciences
2008 Phase 2 NCT00626678 Iran, Islamic Republic of;
West China Hospital, Sichuna University
2019 - ChiCTR1800020382 China;
argenx
2021 Phase 3 NCT04598477 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 NCT04598451 Australia;Bulgaria;China;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
Prednisone/Prednisolone
GlaxoSmithKline
2015 Phase 3 NCT02613910 United States;
RO0452294/V02
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
RO1061443/F02
F. Hoffmann-La Roche Ltd
2015 Phase 3 EUCTR2014-000382-41-IT Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-FR Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-ES Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2014-000382-41-DE Argentina;Australia;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
Recombinant human interleukin-2 (rhIL-2)
Second Xiangya Hospital of Central South University
2020 Phase 2 NCT04023149 China;
Rilzabrutinib Oral Tablet
Principia Biopharma, a Sanofi Company
2019 Phase 3 NCT03762265 Argentina;Australia;Brazil;Bulgaria;Canada;Croatia;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Rituximab
Department of Dermatology,Keio University School of Medicine
2016 Phase 2 JPRN-UMIN000024265 Japan;
2014 Phase 1,2 JPRN-UMIN000015451 Japan;
Funakoshi Takeru
2017 - JPRN-jRCTs031180405 Japan;
Hoffmann-La Roche
2015 Phase 3 NCT02383589 Argentina;Australia;Brazil;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine;United States;
ISTITUTO DERMOPATICO IMMACOLATA
2007 - EUCTR2007-005711-26-IT Italy;
Kanaoka Miwa
2014 - JPRN-jRCTs031180220 Japan;
Keio University, School of Medicine
2017 - JPRN-UMIN000026004 Japan;
Rabin Medical Center
2010 - NCT01338103 Israel;
Research group of rare intractable dermatologial disorder
2010 Phase 2 JPRN-UMIN000004428 Japan;
The University of Hong Kong
2020 Phase 2 NCT04400994 Hong Kong;
University Hospital, Rouen
2019 Phase 3 NCT03790293 -
2011 Phase 3 NCT01299857 France;
2009 Phase 3 NCT00784589 France;
West China Hospital, Sichuna University
2019 - ChiCTR1800020382 China;
Rituximab (MABTHERA® or RITUXAN®).
University Hospital, Toulouse
2009 - NCT00960713 France;
Rituximab and Cyclophosphamide IV
Uprety Shraddha
2013 Phase 3 NCT01974518 India;
Sirolimus (formerly known as Rapamycin)
University of California, Irvine
2011 Early Phase 1 NCT01313923 United States;
TPM203
Topas Therapeutics GmbH
2019 Phase 1 EUCTR2019-001727-12-DE Germany;Israel;Italy;United Kingdom;
Tirabrutinib
ONO PHARMACEUTICAL CO.,LTD.
2019 Phase 2 JPRN-JapicCTI-184231 Japan;
Triamcinolone Acetonide
Cairo University
2016 Phase 3 NCT02828163 Egypt;
VAY736
Novartis Pharma Services AG
2013 Phase 2 EUCTR2013-001217-33-AT Austria;Bulgaria;Taiwan;United States;
Novartis Pharmaceuticals
2013 Phase 2 NCT01930175 Austria;Bulgaria;Germany;Israel;Italy;Taiwan;United Kingdom;United States;
WATER FOR INJECTION
Ruprecht-Karls-University Heidelberg
2013 Phase 2 EUCTR2013-000211-24-DE Germany;